Product Description
an Orexin Receptor Antagonist. YZJ-1139(1) contains the azabicyclic nortropane structure with three chiral centers. (Sourced from: https://pubs.acs.org/doi/full/10.1021/acs.oprd.1c00457)
Mechanisms of Action: OX2R Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Huazhong University of Science Tongji Hospital, Tongji Medical College
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Insomnia
Phase 1: Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06975514 |
YZJ-1139-3-02 | P3 |
Recruiting |
Insomnia |
2025-08-01 |
14% |
2025-05-17 |
Primary Endpoints|Treatments |
NCT06671444 |
YZJ-1139-1-12 | P1 |
Active, not recruiting |
Insomnia|Kidney Diseases |
2024-11-10 |
48% |
2024-11-05 |
Primary Endpoints|Treatments |
CTR20242936 |
CTR20242936 | P1 |
Completed |
Insomnia |
2024-09-19 |
2026-01-18 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06680531 |
YZJ-1139-1-14 | P1 |
Active, not recruiting |
Insomnia |
2024-09-18 |
37% |
2024-11-09 |
Primary Endpoints|Treatments |
CTR20242889 |
CTR20242889 | P1 |
Completed |
Insomnia |
2024-09-13 |
2026-01-11 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06671470 |
YZJ-1139-1-13 | P1 |
Active, not recruiting |
Insomnia |
2024-09-13 |
37% |
2024-11-05 |
Primary Endpoints |
CTR20240440 |
CTR20240440 | P1 |
Completed |
Insomnia |
2024-04-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06671509 |
YZJ-1139-1-11 | P1 |
Completed |
Insomnia |
2024-04-18 |
2024-11-05 |
Primary Endpoints|Treatments |
|
CTR20250036 |
CTR20250036 | P3 |
Completed |
Insomnia |
2025-07-21 |
2025-12-14 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241147 |
CTR20241147 | P1 |
Completed |
Insomnia |
2024-11-06 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2020 |
News Article |
Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com |